Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $8.5 million.

  • Krystal Biotech's Capital Expenditures rose 717.39% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 11.45%. This contributed to the annual value of $8.5 million for FY2024, which is 27.99% down from last year.
  • Krystal Biotech's Capital Expenditures amounted to $8.5 million in FY2024, which was down 27.99% from $11.8 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Capital Expenditures ranged from a high of $68.3 million in FY2021 and a low of $8.5 million during FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $11.8 million (2023), whereas its average is $24.4 million.
  • As far as peak fluctuations go, Krystal Biotech's Capital Expenditures spiked by 360.39% in 2021, and later tumbled by 77.73% in 2023.
  • Yearly analysis of 5 years shows Krystal Biotech's Capital Expenditures stood at $14.8 million in 2020, then skyrocketed by 360.39% to $68.3 million in 2021, then declined by 22.47% to $53.0 million in 2022, then tumbled by 77.73% to $11.8 million in 2023, then declined by 27.99% to $8.5 million in 2024.